dc.contributor.author | Lin, P | |
dc.contributor.author | Min, M | |
dc.contributor.author | Lee, M | |
dc.contributor.author | Holloway, L | |
dc.contributor.author | Forstner, D | |
dc.contributor.author | Bray, V | |
dc.contributor.author | Xuan, W | |
dc.contributor.author | Chicco, A | |
dc.contributor.author | Fowler, A | |
dc.date.accessioned | 2021-12-15T01:22:05Z | |
dc.date.available | 2021-12-15T01:22:05Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0167-8140 | |
dc.identifier.doi | 10.1016/j.radonc.2016.05.021 | |
dc.identifier.uri | http://hdl.handle.net/10072/410796 | |
dc.description.abstract | Purpose To evaluate the prognostic value of 18F-FDG-PET-CT performed prior to (prePET) and during the third week (iPET) of radiation therapy (RT) in nasopharyngeal carcinoma (NPC). Materials and methods Thirty-patients with newly diagnosed loco-regionally advanced NPC treated with radical RT underwent prePET and iPET. The median follow-up was 26 months (8–66.9). The maximum-standardised-uptake-value (SUVmax), metabolic-tumour-volume (MTV) and total-lesional-glycolysis (TLG) of the primary tumour (PT), index-node (IN) (lymph node with highest TLG), total-lymph-nodes (TN) and combined primary-tumour and nodal (PTN), and their % reductions in iPET were analysed, and results were correlated with 2-year Kaplan–Meier loco-recurrence-free-survival (LRFS), regional-failure-free-survival (RFFS), distant-metastatic-failure-free-survival (DMFFS), disease-free-survival (DFS), and overall-survival (OS). Optimal-cutoffs (OC) were derived from Receiver-Operating-Characteristic curves. Results For LRFS, the only predictor was reduction in PT MTV by >50%: 95.2% vs. 75.0%, p = 0.024. For other treatment outcomes, only nodal or PTN predicted outcomes. The IN SUVmax (pre-PET-OC = 10.45 g/mL and iPET-OC = 8.15) and TLG (prePET-OC = 90 g and iPET-OC = 33.4) were the best predictors of outcome: RFFS (iPET SUVmax/TLG): 100% vs. 50%, p < 0.001 and 100% vs. 44%, p = 0.032; DMFFS (prePET SUVmax/TLG); 100% vs. 51.9%, p = 0.004 and 100% vs. 47.6%, p = 0.002; DFS (prePET TLG and iPET SUVmax): 87.5% vs. 33%, p = 0.045 and 78.7% vs. 20%, p = 0.01; and OS (prePET TLG): 100% vs 66.3%, p = 0.036. Conclusions We have demonstrated IN of prePET and iPET to be a feasible and potentially useful novel imaging biomarker to predict for patients with NPC who have a high risk of regional or distant metastatic failure. Future work is required to validate our findings in a well-powered, prospective study with a standardised treatment protocol, and their potential use to guide individualised therapy for NPC. | |
dc.description.peerreviewed | Yes | |
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartofpagefrom | 87 | |
dc.relation.ispartofpageto | 91 | |
dc.relation.ispartofissue | 1 | |
dc.relation.ispartofjournal | Radiotherapy and Oncology | |
dc.relation.ispartofvolume | 120 | |
dc.subject.fieldofresearch | Other physical sciences | |
dc.subject.fieldofresearch | Oncology and carcinogenesis | |
dc.subject.fieldofresearch | Clinical sciences | |
dc.subject.fieldofresearch | Medical and biological physics | |
dc.subject.fieldofresearchcode | 5199 | |
dc.subject.fieldofresearchcode | 3211 | |
dc.subject.fieldofresearchcode | 3202 | |
dc.subject.fieldofresearchcode | 5105 | |
dc.subject.keywords | Adaptive radiotherapy | |
dc.subject.keywords | FDG | |
dc.subject.keywords | Imaging biomarker | |
dc.subject.keywords | Nasopharyngeal carcinoma | |
dc.subject.keywords | PET CT | |
dc.title | Prognostic utility of 18F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Lin, P; Min, M; Lee, M; Holloway, L; Forstner, D; Bray, V; Xuan, W; Chicco, A; Fowler, A, Prognostic utility of 18F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site, Radiotherapy and Oncology, 2016, 120 (1), pp. 87-91 | |
dcterms.dateAccepted | 2016-05-20 | |
dc.date.updated | 2021-12-15T01:20:49Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Min, Myo | |